Interventions for chronic palmoplantar pustulosis

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 1, 2020, Pages

  Obeid, Grace ^a   Do, Giao ^b   Kirby, Lisa ^c   Hughes, Carolyn ^d   Sbidian, Emilie ^b,e   Le Cleach, Laurence ^b,e  

^a Sacre Coeur Hospital Baabda   (Lebanon)

^b HENRI MONDOR HOSPITAL   (France)

^c QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e Centre d'Investigation Clinique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALITRETINOIN; ALUMINUM CHLORIDE; ANTIBIOTIC AGENT; CLOBETASOL; COLCHICINE; CYCLOSPORINE; DERMATOLOGICAL AGENT; ETRETINATE; GUSELKUMAB; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PSORALEN; RETINOID; RETINOL; SECUKINUMAB; TETRACYCLINE DERIVATIVE; TRIAMCINOLONE ACETONIDE; USTEKINUMAB; VITAMIN; ANTIINFECTIVE AGENT; CORTICOSTEROID; MONOCLONAL ANTIBODY;

ANKLE SWELLING; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BLISTER; CHEILITIS; CHRONIC DISEASE; COMBINATION DRUG THERAPY; COMMON COLD; CONFIDENCE INTERVAL; CONJUNCTIVITIS; DATA ANALYSIS; DATA BASE; DATA SYNTHESIS; DISEASE DURATION; DISEASE SEVERITY; ERYTHEMA; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; INFORMATION PROCESSING; JOINT SWELLING; LONG TERM CARE; NAUSEA; OINTMENT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; PUSTULOSIS PALMOPLANTARIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; RHINOPHARYNGITIS; RISK ASSESSMENT; SELECTION BIAS; SENSITIVITY ANALYSIS; SKIN IRRITATION; SYSTEMATIC REVIEW; TOPICAL DRUG ADMINISTRATION; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; URINARY TRACT DISEASE; ADULT; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS; QUALITY OF LIFE; RASH; ULTRAVIOLET RADIATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; ULTRAVIOLET RAYS; USTEKINUMAB;

EID: 85077982761     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011628.pub2     Document Type: Article

References (120)

1. Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. British Journal of Dermatology 2001;145(4):546-53. [CENTRAL: CN-00375323; PUBMED: 11703279]x-wiley/crsRef/12668164
2. Bhushan M, Burden AD, McElhone K, Vanhoutte FP, Griffiths CEM. A double-blinded placebo controlled study of oral liarozole in the treatment of palmoplantar pustular psoriasis. Abstract 34, International Congress 'Psoriasis: from gene to clinic'. British Journal of Dermatology 1999;141(5):978. [CENTRAL: CN-00428744]x-wiley/crsRef/12668165
3. Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J, et al. Etanercept in the treatment of palmoplantar pustulosis. Journal of Drugs in Dermatology 2008;7(10):940-6. [CENTRAL: CN-00664757; PUBMED: 19112757]x-wiley/crsRef/12668167
4. Bissonnette R, Lynde CW, Krueger JG, Tan J, Nigen S, Langley R.B. Interleukins-23 and -17 in patients with palmoplantar pustular psoriasis and palmoplantar pustulosis. Journal of the European Academy of Dermatology and Venereology 2014;28(10):1298-305. [PUBMED: 24112799]x-wiley/crsRef/12668169
5. Cazzaniga S, Lo Scocco G, Schincaglia E, Mercuri SR, Chimenti S, Saraceno R, et al. Randomized, within-patient, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar pustulosis. Dermatology (Basel, Switzerland) 2014;228(2):166-71. [CENTRAL: CN-00991953; PUBMED: 24434748]x-wiley/crsRef/12668171
6. Erkko P, Granlund H, Remitz A, Rosen K, Mobacken H, Lindelof B, et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. British Journal of Dermatology 1998;139(6):997-1004. [CENTRAL: CN-00159869; PUBMED: 9990362]x-wiley/crsRef/12668173
7. Fairris GM, Jones DH, Mack DP, Rowell NR. Superficial X-ray therapy in the treatment of palmoplantar pustulosis. British Journal of Dermatology 1984;111(4):499-500. [CENTRAL: CN-00568893; PUBMED: 6386034]x-wiley/crsRef/12668175
8. Foged E, Holm P, Larsen PO, Laurberg G, Reymann F, Roesdahle K, et al. A randomized trial of etretinate (Tigason) in palmoplantar pustulosis. Dermatologica 1983;166(4):220-3. [CENTRAL: CN-00031137; PUBMED: 6343149]x-wiley/crsRef/12668177
9. Fredriksson T. Oral treatment of psoriasis and pustulosis palmo-plantaris with Ro 10-9359. Dermatologica 1978;157(Suppl 1):13-8. [CENTRAL: CN-00499373; PUBMED: 150982]x-wiley/crsRef/12668180
10. Fredriksson T, Pettersson U. Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. Dermatologica 1979;158(1):60-4. [CENTRAL: CN-00019698; Pubmed: 153863]x-wiley/crsRef/12668179
11. Hattel T, Sondergaard J. Pustulosis palmaris et plantaris treated with hydroxyurea. Acta Dermato-venereologica 1974;54(2):152-4. [CENTRAL: CN-00010203; PUBMED: 4133022]x-wiley/crsRef/12668182
12. Jansen C, Hollmén A, Pajarre R. Peroral aromatic retinoid treatment of palmoplantar pustulosis: double-blind comparison of Ro 10-9359 and placebo. Acta Dermato-venereologica 1979;59(3):271-3. [CENTRAL: CN-00020396; Pubmed: 87093]x-wiley/crsRef/12668184
13. Kragballe K, Larsen FG. A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta Dermato-venereologica 1991;71(6):540-2. [CENTRAL: CN-00081448; PUBMED: 1685841]x-wiley/crsRef/12668186
14. Lassus A, Lauharanta J, Juvakoski T, Kanerva L. Efficacy of etretinate (Tigason) in clearing and prevention of relapse of palmoplantar pustulosis. Dermatologica 1983;166(4):215-9. [CENTRAL: CN-00031136; PUBMED: 6343148]x-wiley/crsRef/12668188
15. Lassus A, Lauharanta J, Eskelinen A. The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis. British Journal of Dermatology 1985;112(4):455-9. [CENTRAL: CN-00568680; PUBMED: 3888246]x-wiley/crsRef/12668190
16. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. British Journal of Dermatology 1988;119(6):755-9. [CENTRAL: CN-00057015; PUBMED: 2974306]x-wiley/crsRef/12668192
17. Lawrence CM, Marks J, Parker S, Shuster S. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. British Journal of Dermatology 1984;110(2):221-6. [CENTRAL: CN-00033676; PUBMED: 6696838]x-wiley/crsRef/12668194
18. Layton AM, Sheehan-Dare R, Cunliffe WJ. A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. British Journal of Dermatology 1991;124(6):581-4. [CENTRAL: CN-00076516; PUBMED: 2064943]x-wiley/crsRef/12668196
19. Lindelof B, Beitner H. The effect of grenz ray therapy on pustulosis palmoplantaris. A double-blind bilateral trial. Acta Dermato-venereologica 1990;70(6):529-31. [CENTRAL: CN-00073682; PUBMED: 1981434]x-wiley/crsRef/12668198
20. Matsunami E, Takashima A, Mizuno N, Jinno T, Ito H. Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections. Journal of Dermatology 1990;17(2):92-6. [CENTRAL: CN-00067169; PUBMED: 2184179]x-wiley/crsRef/12668200
21. Mrowietz U, Bachelez H, Burden AD, Rissler M, Sieder C, Orsenigo R, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. Journal of the American Academy of Dermatology 2019;80(5):1344-52. [PUBMED: 30716404]x-wiley/crsRef/12668202
22. Muro M, Kawakami H, Matsumoto Y, Abe N, Tsuboi R, Okubo Y. Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: a prospective, randomised,left-right comparison study. Journal of Dermatological Treatment 2016;27(1):51-3. [CENTRAL: CN-01257303; PUBMED: 26108445]x-wiley/crsRef/12668204
23. Murray D, Corbett MF, Warin AP. A controlled trial of photochemotherapy for persistent palmoplantar pustulosis. British Journal of Dermatology 1980;102(6):659-63. [CENTRAL: CN-00023617; PUBMED: 7000136]x-wiley/crsRef/12668206
24. Murray D, Warin AP. Photochemotherapy for persistent palmoplantar pustulosis (PPP). British Journal of Dermatology 1979;101(Suppl 17):13-4. [CENTRAL: CN-00568675; Pubmed: 380623]x-wiley/crsRef/12668207
25. NCT02641730. An efficacy and safety of guselkumab in participants with palmoplantar pustulosis. clinicaltrials.gov/ct2/show/NCT02641730 (first received 29 December 2015). x-wiley/crsRef/12668209
26. Nielsen PG, Madsen SM. Occlusive treatment of palmoplantar pustular psoriasis with clobetasol propionate ointment succeeded by short-term PUVA. Journal of Dermatological Treatment 1995;6(2):77-9. [CENTRAL: CN-00199646]x-wiley/crsRef/12668211
27. Reich K, Graff O, Mehta N. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomised phase II study. British Journal of Dermatology 2016;174(6):1277-81. [CENTRAL: CN-01166541]x-wiley/crsRef/12668213
28. Reitamo S, Erkko P, Remitz A, Lauerma AI, Montonen O, Harjula K. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Archives of Dermatology 1993;129(10):1273-9. [CENTRAL: CN-00096600; PUBMED: 8215491]x-wiley/crsRef/12668215
29. Rodriguez MS, Martin-Neda FG, Bustinduy MG, Alom SD, Garcia ME, Gonzalez RS, et al. Aluminium chloride hexahydrate in the treatment of palmoplantar pustulosis. A preliminary study [Cloruro de aluminio hexahidratado en el tratamiento de las pustulosis palmoplantares. Estudio preliminar]. Actas Dermo-sifiliograficas 2000;91(9):416-9. [CENTRAL: CN-00424502]x-wiley/crsRef/12668217
30. Rosen K, Mobacken H, Swanbeck G. PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris. A placebo-controlled comparative trial. Archives of Dermatology 1987;123(7):885-9. [CENTRAL: CN-00048987; PUBMED: 3300565]x-wiley/crsRef/12668219
31. Schroder K, Zaun H, Holzmann H, Altmeyer P, el-Gammal S. Pustulosis palmo-plantaris. Clinical and histological changes during etretin (acitretin) therapy. Acta Dermato-venereologica. Supplementum 1989;146:111-6. [CENTRAL: CN-00064908; PUBMED: 2532841]x-wiley/crsRef/12668221
32. Su LN, Ren J, Cheng SM, Liu JL, Ding YF, Zhu NW. UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomised controlled study. Lasers in Medical Science 2017;32(8):1819-23. [CENTRAL: CN-01446891; PUBMED: 28699044]x-wiley/crsRef/12668223
33. Terui T, Kobayashi S, Okubo Y, Murakami M, Hirose K, Kubo H. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatology 2018;154(3):309-16. [PUBMED: 29417135]x-wiley/crsRef/12668225
34. Thestrup-Pedersen K, Reymann F. Treatment of pustulosis palmaris et plantaris with colchicine. A double-blind cross-over trial. Acta Dermato-venereologica 1984;64(1):76-8. [CENTRAL: CN-00034679; PUBMED: 6203289]x-wiley/crsRef/12668227
35. Thomsen K, Osterbye P. Pustulosis palmaris et plantaris. British Journal of Dermatology 1973;89(3):293-6. [CENTRAL: CN-00009126; PUBMED: 4582718]x-wiley/crsRef/12668229
36. Thune P. Treatment of palmoplantar pustulosis with Tigason. Dermatologica 1982;164(1):67-72. [CENTRAL: CN-00384407; PUBMED: 7040131]x-wiley/crsRef/12668231
37. Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: a randomised, double-blind, placebo-controlled trial. Journal of Dermatology 2016;43(3):288-93. [CENTRAL: CN-01141237; PUBMED: 26282062]x-wiley/crsRef/12668233
38. Ward JM, Corbett MF, Hanna MJ. A double-blind trial of clomocycline in the treatment of persistent palmoplantar pustulosis. British Journal of Dermatology 1976;95(3):317-22. [CENTRAL: CN-00014806; PUBMED: 788767]x-wiley/crsRef/12668235
39. White SI, Marks JM, Shuster S. Etretinate in pustular psoriasis of palms and soles. British Journal of Dermatology 1985;113(5):581-5. [CENTRAL: CN-00040409; PUBMED: 3904810]x-wiley/crsRef/12668237
40. White SI, Puttick L, Marks JM. Low-dose etretinate in the maintenance of remission of palmoplantar pustular psoriasis. British Journal of Dermatology 1986;115(5):577-82. [CENTRAL: CN-00045794; PUBMED: 3539171]x-wiley/crsRef/12668239
41. Aso K, Amano N. Inhibitory effect of retinoid (RO 10-9359) on chemotaxis and random migration of polymorphonuclear leucocytes in patients with pustulosis palmaris et plantaris. Nihon Hifuka Gakkai Zasshi 1983;93(3):333-7. x-wiley/crsRef/12668241
42. Carr D, Tusa MG, Carroll CL, Pearce DJ, Camacho F, Kaur M, et al. Open label trial of alefacept in palmoplantar pustular psoriasis. Journal of Dermatological Treatment 2008;19(2):97-100. [PUBMED: 18512272]x-wiley/crsRef/12668243
43. Cassano N, Mantegazza R, Battaglini S, Apruzzi D, Loconsole F, Vena GA. Adjuvant role of a new emollient cream in patients with palmar and/or plantar psoriasis: a pilot randomized open-label study. Giornale Italiano di Dermatologia e Venereologia 2010;145(6):789-92. [CENTRAL: CN-00785934; Pubmed: 21139557]x-wiley/crsRef/12668245
44. Dupre A, Christol B, Cassagnaveres E, Bazex J. Atypical palmoplantar psoriasis and related syndromes [Psoriasis palmo-plantaires atypiques et syndromes apparentes]. Cahiers de Medecine 1973;14(8):681-8. [PUBMED: 4602471]x-wiley/crsRef/12668247
45. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, al-Alem S, Abdulla SA. Occlusive versus nonocclusive calcipotriol ointment treatment for palmoplantar psoriasis. International Journal of Tissue Reactions 2001;23(2):59-62. [CENTRAL: CN-00373257; Pubmed: 11447774]x-wiley/crsRef/12668249
46. Engin B, Oguz O. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses. International Journal of Dermatology 2005;44(4):337-9. [CENTRAL: CN-00575420; PUBMED: 15811091]x-wiley/crsRef/12668251
47. Fritsch P, Honigsmann H, Jashcke E, Wolff K. Photochemotherapy of psoriasis: increasing its effectiveness with an oral aromatic retinoid (clinical results in 134 patients). Deutsche Medizinische Wochenschrift (1946) 1978;103(44):1731-6. [CENTRAL: CN-00019171]x-wiley/crsRef/12668253
48. Gjertsen BT, Nilsen A. Local treatment of psoriasis and pustulosis palmoplantaris with desoxymethasone ointment 0.25%. Tidsskr Nor Laegeforen 1980;100(11):632-3. [PUBMED: 6992336]x-wiley/crsRef/12668255
49. Grundmann-Kollmann M, Behrens S, Peter RU, Kerscher M. Treatment of severe recalcitrant dermatoses of the palms and soles with PUVA-bath versus PUVA-cream therapy. Photodermatology, Photoimmunology & Photomedicine 1999;15(2):87-9. [CENTRAL: CN-00162994; PUBMED: 10321522]x-wiley/crsRef/12668257
50. Gupta SK, Singh KK, Lalit M. Comparative therapeutic evaluation of different topicals and narrow band ultraviolet B therapy combined with systemic methotrexate in the treatment of palmoplantar psoriasis. Indian Journal of Dermatology 2011;56(2):165-70. [CENTRAL: CN-00843779; PUBMED: 21716541]x-wiley/crsRef/12668259
51. Hofer A, Fink-Puches R, Kerl H, Quehenberger F, Wolf P. Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet: a therapy for chronic palmoplantar psoriasis. Photodermatology, Photoimmunology & Photomedicine 2006;22(1):1-5. [CENTRAL: CN-00562268; PUBMED: 16436174]x-wiley/crsRef/12668261
52. Janagond AB, Kanwar AJ, Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. Journal of the European Academy of Dermatology and Venereology 2013;27(3):e384-9. [CENTRAL: CN-01124551; PUBMED: 23066720]x-wiley/crsRef/12668263
53. Khandpur S, Sharma VK. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. Clinical and Experimental Dermatology 2011;36(6):613-6. [CENTRAL: CN-00800550; PUBMED: 21507036]x-wiley/crsRef/12668265
54. Kumar B, Kumar R, Kaur I. Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle?. International Journal of Dermatology 1997;36(4):309-12. [CENTRAL: CN-00140118; PUBMED: 9169338]x-wiley/crsRef/12668267
55. Mehta BH, Amladi ST. Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: an observer-blinded randomized controlled study. Indian Journal of Dermatology 2011;56(1):40-3. [CENTRAL: CN-00861405; PUBMED: 21572790]x-wiley/crsRef/12668269
56. Neumann NJ, Mahnke N, Korpusik D, Stege H, Ruzicka T. Treatment of palmoplantar psoriasis with monochromatic excimer light (308-nm) versus cream PUVA. Acta Dermato-venereologica 2006;86(1):22-4. [CENTRAL: CN-00563926; PUBMED: 16585984]x-wiley/crsRef/12668271
57. Orfanos CE, Goerz G. Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results) (author's transl) [Orale psoriasis-Therapie mit einem neuen aromatischen Retinoid (Ro 10-9359). Eine multizentrische kontrollierte Studie an 291 Patienten in der Bundesrepublik. Vorlaufige Mitteilung]. Deutsche Medizinische Wochenschrift (1946) 1978;103(5):195-9. [CENTRAL: CN-00017768; PUBMED: 631039]x-wiley/crsRef/12668273
58. Papp K, Hu A, Wasel N, Day R. Apremilast is effective in the treatment of scalp and palmoplantar psoriasis: results from a phase II2b randomized, controlled study. Journal of the American Academy of Dermatology. 2012; Vol. 66:AB185. x-wiley/crsRef/12668275
59. Rosen K, Jontell M, Mobacken H, Rosdahl I. Epidermal Langerhans' cells in patients with pustulosis palmoplantaris treated with etretinate or etretinate + methoxsalen photochemotherapy. Acta Dermato-venereologica 1988;68(3):218-23. [CENTRAL: CN-00054561; PUBMED: 2455414]x-wiley/crsRef/12668277
60. Schiener R, Gottlober P, Muller B, Williams S, Pillekamp H, Peter RU, et al. PUVA-gel vs. PUVA-bath therapy for severe recalcitrant palmoplantar dermatoses. A randomized, single-blinded prospective study. Photodermatology, Photoimmunology & Photomedicine 2005;21(2):62-7. [CENTRAL: CN-00513404; PUBMED: 15752122]x-wiley/crsRef/12668279
61. Sezer E, Erbil AH, Kurumlu Z, Tastan HB, Etikan I. Comparison of the efficacy of local narrowband ultraviolet B (NB-UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology 2007;34(7):435-40. [CENTRAL: CN-00610281; PUBMED: 17584319]x-wiley/crsRef/12668281
62. Thaci D, Xie J, Mulani P, Gupta S. Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol on patient-reported outcomes in patients with palmoplantar, nail, or scalp psoriasis. Journal of the American Academy of Dermatology 2010;62(3 Suppl):AB 135. [CENTRAL: CN-00843899]x-wiley/crsRef/12668283
63. Yaniv S, Gottlieb A, Wang A, Michelon M, Dumont N, Au SC, et al. An investigator-initiated, open-label study evaluating the efficacy and safety of ustekinumab in patients with moderate to severe palmar plantar psoriasis. Journal of the American Academy of Dermatology. 2012:AB185. x-wiley/crsRef/12668285
64. Zhang J, Hu F-H, Li L-M, Zhu W-Y. Observation on topical tacalcitol ointment in the treatment of twenty-seven patients with palmoplantar pustulosis. Journal of Clinical Dermatology 2007;36(5):328-9. [CENTRAL: CN-00640929]x-wiley/crsRef/12668287
65. EudraCT 2006-004519-23. Comparison of fumaric acid ester-PUVA versus PUVA-etretinate in palmoplantar pustulosis. www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004519-23 (first received 10 February 2009). x-wiley/crsRef/12668289
66. Fenton DA, English JS, Wilkinson JD. A controlled trial using a lipoxygenase inhibitor (benoxaprofen) in the treatment of persistent palmoplantar pustulosis. British Journal of Dermatology 1983;109(Suppl 24):25-6. [CENTRAL: CN-00400885]x-wiley/crsRef/12668291
67. Mann RJ. Failure of colchicine for palmo-plantar pustulosis. British Journal of Dermatology 1982;106(3):373. [CENTRAL: CN-00568966; PUBMED: 7039659]x-wiley/crsRef/12668293
68. NCT03135548. Initial dosing of BI 655130 in palmoplantar pustulosis patients. clinicaltrials.gov/NCT03135548 (first received 1 May 2017). x-wiley/crsRef/12668295
69. ISRCTN13127147. Treatment of pustular psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies. www.isrctn.com/ISRCTN13127147 (first received 1 August 2016). x-wiley/crsRef/12668297
70. NCT03633396. A study to evaluate the efficacy and safety of ANB019 in subjects with palmoplantar pustulosis (PPP) [A phase II, randomized, placebo-controlled, double-blind, multiple dose study to evaluate the efficacy and safety of ANB019 in subjects with palmoplantar pustulosis]. clinicaltrials.gov/ct2/show/NCT03633396 (first received 16 August 2018). x-wiley/crsRef/12668299
71. Adisen E, Gürer MA. Therapeutic options for palmoplantar pustulosis. Clinical & Experimental Dermatology 2010;35(3):219-22. [PUBMED: 19874337]
72. Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaëlsson G, Evans J, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. Journal of Investigative Dermatology 2003;120(4):627-32. [PUBMED: 12648227]
73. Barber HW. Acrodermatitis continua vel perstans (dermatitis repens) and psoriasis pustule. British Journal of Dermatology 1930;42:500-18. [DOI: 10.1111/j.1365-2133.1930.tb09380.x]
74. Brunasso AM, Massone C. Can we really separate palmoplantar pustulosis from psoriasis?. Journal of the European Academy of Dermatology and Venereology 2010;24(5):619-21. [PUBMED: 20337817]
75. Brunasso AM, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. British Journal of Dermatology 2013;168(6):1243-51. [PUBMED: 23301847]
76. Burden AD, Kemmett D. The spectrum of nail involvement in palmoplantar pustulosis. British Journal of Dermatology 1996;134(6):1079-82. [PUBMED: 8763428]
77. Chen X, Yang M, Cheng Y, Liu GJ, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD009481.pub2]
78. Cochran WG. The comparison of percentages in matched samples. Biometrika 1950;37(3-4):256–66. [PUBMED: 14801052]
79. Cochrane Skin. Core Outcome Set Initiative. cs-cousin.org (accessed 8 July 2019).
80. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. Journal of Investigative Dermatology 2009;129(6):1339-50. [PUBMED: 19322214]
81. Elder D, Elenitsas R, Johnson B, Murphy G, Xu G (editors). Lever's Histopathology of the Skin. 10th Edition. Philadelphia: Lippincott Williams & Wilkins, 2008.
82. Eriksson MO, Hagforsen E, Lundin IP, Michaëlsson G. Palmoplantar pustulosis: a clinical and immunohistological study. British Journal of Dermatology 1998;138(3):390-8. [PUBMED: 9580788]
83. Floristan U, Feltes R, Ramírez P, Alonso ML, De Lucas R. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Pediatric Dermatology 2011;28(3):349-50. [PUBMED: 21371112]
84. Fujishima S, Watanabe H, Kawaguchi M, Suzuki T, Matsukura S, Homma T, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Archives of Dermatological Research 2010;302(7):499-505. [PUBMED: 20148256]
85. Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. British Journal of Dermatology 2007;156(2):258-62. [PUBMED: 17223864]
86. Hagforsen E, Awder M, Lefvert AK, Nordlind K, Michaëlsson G. Palmoplantar pustulosis: an autoimmune disease precipitated by smoking?. Acta Dermato-venereologica 2002;82(5):341-6. [PUBMED: 12430732]
87. Hellgren L, Mobacken H. Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis. Acta Dermato-venereologica 1971;51(4):284-8. [PUBMED: 4105777]
88. Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clinical Trials 2008;5(3):225-39. [PUBMED: 18559412]
89. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
90. Hirji KF, Fagerland MW. Calculating unreported confidence intervals for paired data. BMC Medical Research Methodology 2011;11:66. [PUBMED: 21569392]
91. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK506. Clinical Immunology & Immunopathology 1996;80(3 Pt 2):S40-5. [PUBMED: 8811062]
92. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007;176(8):1091-6. [PUBMED: 17420491]
93. Kaneko T, Murakami M, Kishibe M, Brattsand M, Morhenn VB, Ishida-Yamamoto A, et al. Over-expression of kallikrein related peptidases in palmoplantar pustulosis. Journal of Dermatological Science 2012;67(1):73-6. [PUBMED: 22520926]
94. Kikuchi N, Yamamoto T. Dental infection as a triggering factor in palmoplantar pustulosis. Acta Dermato-venereologica 2013;93(6):721-2. [PUBMED: 23462950]
95. Kurian A, Barankin B. Current effective topical therapies in the management of psoriasis. Skin Therapy Letter 2011;16(1):4-7. [PUBMED: 21293834]
96. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. New England Journal of Medicine 2014;371(4):326-38. [PUBMED: 25007392]
97. Le Cleach L, Trinquart L, Lebrun-Vignes B, Giraudeau B, Chosidow O. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD009036]
98. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. Journal of Investigative Dermatology 2013;133(1):17-26. [PUBMED: 22673731]
99. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nature Immunology 2009;10(3):314-24. [PUBMED: 19182808]
100. Michaëlsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. Journal of the American Academy of Dermatology 2006;54(4):737-8. [PUBMED: 16546609]
101. Michaëlsson G, Kristjánsson G, Pihl Lundin I, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. British Journal of Dermatology 2007;156(4):659-66. [PUBMED: 17263812]
102. Miot HA, Miot LD, Lopes PS, Haddad GR, Marques SA. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. Journal of the American Academy of Dermatology & Venereology 2009;23(10):1173-7. [PUBMED: 19453779]
103. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357(9263):1191-4. [MEDLINE: 11323066]
104. Morales-Múnera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. British Journal of Dermatology 2013;168(4):820-4. [PUBMED: 23210683]
105. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. Journal of the American Academy of Dermatology 2009;61(3):486-504. [PUBMED: 19628303]
106. Murakami M, Ohtake T, Horibe Y, Ishida-Yamamoto A, Morhenn VB, Gallo RL, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. Journal of Investigative Dermatology 2010;130(8):2010-6. [PUBMED: 20393482]
107. Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Experimental Dermatology 2011;20(10):845-7. [PUBMED: 21732985]
108. Otsuka A, Miyachi Y, Kabashima K. Narrowband ultraviolet B phototherapy decreased CCR4+ CD8+ T cells in a patient with palmoplantar pustulosis. Journal of the European Academy of Dermatology & Venereology 2011;25(4):495-6. [PUBMED: 20553356]
109. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. Journal of the American Academy of Dermatology 2003;49(2):271-5. [PUBMED: 12894076]
110. Puig L, Morales-Múnera CE, López-Ferrer A, Geli C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 2012;225(1):14-7. [PUBMED: 22890275]
111. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
112. Rueda-Gotor J, González-Gay MA, Blanco Alonso R, Gonzalez-Vela C, Lopez-Obregon C, González-López MA. Successful effect of tocilizumab in anti-TNF-a-induced palmoplantar pustulosis in rheumatoid arthritis. Joint, Bone, Spine: Revue du Rhumatisme 2012;79(5):510-3. [PUBMED: 22857979]
113. Saurat JH, Lachapelle JM, Lipsker D, Thomas L. Dermatologie et Infections Sexuellement Transmissibles. 5th Edition. Paris: Elsevier Masson, 2009.
114. Schünemann H, Brozek J, Guyatt G, Oxman A, editor(s). Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach (updated October 2013). Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.
115. Uehara M, Ofuji S. The morphogenesis of pustulosis palmaris et plantaris. Archives of Dermatology 1974;109(4):518-20. [PUBMED: 4819106]
116. Watanabe H, Kawaguchi M, Fujishima S, Ogura M, Matsukura S, Takeuchi H, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. Journal of Investigative Dermatology 2009;129(3):650-6. [PUBMED: 18830271]
117. Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D. Fitzpatrick's Dermatology in General Medicine. 7th Edition. New York: McGraw-Hill Professional, 2008.
118. Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Archives of Dermatological Research 2012;304(6):465-9. [PUBMED: 22426986]
119. Chalmers R, Hollis S, Leonardi-Bee J, Griffiths CEM, Marsland Bsc MRCP A. Interventions for chronic palmoplantar pustulosis. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD001433.pub2]
120. Obeid G, Do G, Katsahian S, Kirby L, Hughes C, Le Cleach L. Interventions for chronic palmoplantar pustulosis. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD011628]